Srinivas Ghatta, PhD has over 22 years of Industrial experience in pharmaceutical sciences research and development.  He received his first M.S. in Pharmacology and Toxicology at National Institute of Pharmaceutical Research (NIPER) in India and second was from Drexel University in Clinical Research Organization and Management.  He completed his PhD at North Dakota State University in Pharmaceutical Sciences.  He was awarded a predoctoral fellowship from American Heart Association.  His research has resulted in over 15 scientific publications.  During his tenure with GSK and Genmab, he was part of Clinical development teams of three approved drugs: Dolutegravir, mepolizumab, and Tisotumab vedotin.